A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Azitra Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06830863
- Locations
- 🇺🇸
NYU Langone, New York, New York, United States
Evaluation of Topical ATR12-351 in Adults with Netherton Syndrome
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Azitra Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06137157
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Study to Evaluate the Safety of ATR-04
Phase 1
Suspended
- Conditions
- Epidermal Growth FactorPapulopustular Rosacea
- Interventions
- Other: Placebo
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Azitra Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04731259
- Locations
- 🇺🇸
RCTS, Inc., Irving, Texas, United States
Safety Study of AZT-04 for Cosmetic Use
Not Applicable
Completed
- Conditions
- Study of Three Doses of AZT-04 for Skin Appearance
- Interventions
- Other: AZT-04
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Azitra Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03820076
- Locations
- 🇺🇸
RCTS, Inc., Irving, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath